华大基因（300676）8月11日主力资金净流出1419.47万元

Group 1 - The core viewpoint of the article highlights the financial performance and market activity of BGI Genomics Co., Ltd. as of August 11, 2025, showing a decline in revenue and net profit compared to the previous year [1] - As of the latest quarterly report, the company reported total revenue of 672 million yuan, a year-on-year decrease of 18.18%, and a net profit attributable to shareholders of 52.6951 million yuan, down 524.87% [1] - The company's liquidity ratios are strong, with a current ratio of 2.854 and a quick ratio of 2.617, while the debt-to-asset ratio stands at 26.68% [1] Group 2 - BGI Genomics has made investments in 71 companies and participated in 42 bidding projects, indicating active engagement in business expansion [2] - The company holds a significant intellectual property portfolio, with 665 trademark registrations and 375 patents, along with 14 administrative licenses [2]